Our second quarter edition spans trending topics across pharma, with a focus on industry responses to the COVID-19 pandemic, including the development and manufacturing of new therapies and vaccines to address COVID-19 and ways to maintain and optimize supply chains and clinical trials.
TriRx Chairman and CEO Tim Tyson reevaluates the responsibilities of different pharma stakeholders during pandemic times.
Nigel Walker analyzes trends in recent U.S. FDA approvals to forecast what to expect in the coming years.
Magnus Schroeder, Ph.D., discusses the company's capabilities for integrated support of COVID-19 programs.
FORMA Therapeutics CEO Frank D. Lee walks us through FORMA's transformation into an integrated biopharma company.
The essentiality of transportation to the pharma industry is even more evident during times of crisis, according to Boyle Transportation's Andrew T. Boyle.
Andrea Baiocchi, Vice President and Site Director for Avara's Liscate, Italy site, provides an overview of the facility's sterile capabilities.
Federal Equipment Company's COO and Counsel Matt Hicks highlights key but often overlooked considerations in ownership of manufacturing equipment.
Tyler Kerr, James Balog, and Andrew Waaso discuss how Albemarle FCS invests proactively to anticipate the future needs of its clients.
Dave Stevens and Jason Rahal discuss how Arranta Bio supports clinical and commercial manufacturing of live biotherapeutic products.
Jeffrey Butler, Ph.D., discusses how SK pharmteco has created an integrated company built around core competencies and centers of excellence and how the company is addressing the COVID-19 pandemic.
Early adoption of innovative technologies drives efficient and cost-effective research services, say Lorraine Rusch, Ph.D., and J. Fred Pritchard, Ph.D.
The Pharma's Almanac editorial team looks back at some of the drug molecules that have had the greatest impact.
Kurt Nielsen, Ph.D., President and CEO of Pii, highlights the company's recent investments in innovative aseptic manufacturing solutions.
Usama Malik and Loretta Itri, M.D., explain how Immunomedics has built a differentiated ADC platform using a proprietary linker and some unique targets.
Alkahest is harnessing chronokines to address neurodegenerative and other aging-related diseases.
A combination of computational drug discovery expertise and drug development capabilities has helped Compugen establish a robust immuno-oncology pipeline.
Abolis Biotechnologies explain how combining metabolic and chemical engineering facilitates efficient production of a range of products.
Franck Mouthon and Mathieu Charveriat, Ph.D., discuss how Theranexus's unique focus on both neurons and astrocytes presents new therapeutic possibilities for neurological disorders.
NeoTx CEO and founder Asher Nathan explains how the company is using the native immune response to fight cancer.
Jeffrey Stein, Ph.D., President and CEO of Cidara Therapeutics, highlights the company's bispecific immunotherapy platform for antiviral vaccines.
James Graham discusses Recce's unique polymeric approach to the development of a new class of antibiotics designed to overcome traditional limitations.
Jeff Wolf explains how Heat Biologics is leveraging a natural warning system to develop an immune platform to target both cancers and infectious diseases.
Acepodia's proprietary Antibody-Cell Conjugation technology allows the development of target cell therapies without the need for genetic engineering.
James E. Brown, President and CEO of DURECT Corporation, discusses the potential of epigenetic regulation in the treatment of organ injury and liver diseases.
Dopamine-somatostatin chimeric compounds show tremendous promise in treating rare endocrine disorders, according to Abraham N. Ceesay, CEO of Tiburio Therapeutics.
Maurice Zauderer discusses why Vaccinex has focused on the disassociation of cellular cytoskeletons to target cancers and neurodegenerative diseases.
David Q. Anderson discusses Ampersand Capital Partners' success in investing in companies in the intersection between healthcare and industrial manufacturing.
Nice Insight's TJ Ladage explores the mosaic of COVID-19 responses across Europe.
Secant Group is developing innovative, bioresorbable textiles to support the next generation of medical devices.
That's Nice plans a 25-country trans-European trip to investigate the future of healthcare.
Globyz Biopharma Services is investing in facilities and temperature-controlled capabilities to become a leading one-stop shop for global comparator sourcing.
The development of innovative and original technology platforms is one of Olon's main drivers as a CDMO supplying APIs to pharmaceutical companies worldwide.
The integration of Bioceros’ capabilities into Polpharma Biologics expands the support for client projects from concept through commercial manufacturing.
TriRx is seeking new innovations to improve operations and has already incorporated robotics, serialization, and cloud-based enterprise resource planning.
Federal Equipment Company leveraged past crisis planning to transition to new operational models during the pandemic without interruptions to their service.
SPI Pharma continues to develop new product innovations while maintaining a focus on their customers' customers, patients.
Innovation at SGD Pharma focuses on increasing patient safety, convenience, flexibility, and additional value to targeted therapies while reducing costs.
Pii continually monitors evolving industry trends and technical innovations to proactively develop solutions and services to overcome potential issues.
SanaClis had crisis contingency plans that enabled the company to ensure the safety of clinical trial participants without interrupting ongoing trials.
Avara’s mission is to provide world-class outsourcing services to help deliver life-changing and life-saving medicines to the patients who need them.
The Pharma’s Almanac team tackles the nature of SARS-CoV-2, development of therapeutics and vaccines, and the broader impacts.
Jo Halliday and Elizabeth Fairley discuss the Talking Medicines' innovative platform designed to capture the patient voice and incorporated it into pharma decision-making.
Globyz Biopharma Services' Salman Pathan and Hector Oyarzun discuss how the increasing complexity of clinical trials demands comprehensive comparator sourcing strategies.
Wayne Hull, Global Chief Digital and Technology Officer for PCI Services, relates the company's recent digital transformation and the benefits already seen.
MilliporeSigma's Thomas Parker, Youness Cherradi, Ph.D., Claire Scanlan, and Elina Gousseinov discuss how depth filtration optimizes clarification of AAVs.
Brian Haney, Ph.D., Director of Technical Operations at AMRI, explains the range of capabilities and services required to support highly potent programs.
Matthew Lakelin discusses TrakCel's cloud-based, personalized cell therapy orchestration platform.
Nice Insight's Gwenaël Servant, Ph.D., predicts some of the changes we will see in pharma supply chains following the COVID-19 pandemic.
A panel of SMEs discusses the industry's response to the COVID-19 pandemic.
A range of experts share their views on the most impactful drug molecules in the industry's history.
We succinctly walk through the main takeaways from the FDA's recent guidance on clinical trials during the pandemic.
.svg)
